Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bliss GVS Pharma has published its audited financial results for Q4 and full year ended March 31, 2026. On a consolidated basis, total income grew 18.2% year-on-year to ₹1,00,064 lakh (₹100 crore), while net profit jumped 49.2% to ₹13,473 lakh (₹134.73 crore). Profit before tax rose even more sharply by ~51% to ₹18,959 lakh, indicating strong operational efficiency. Basic earnings per share on consolidated basis improved from ₹8.02 to ₹12.23. The board has recommended a final dividend of ₹1 per share, subject to shareholder approval at the ensuing AGM.
The sharp nearly 50% rise in net profit is a strong positive signal for shareholders, suggesting robust business growth and margin expansion. The dividend recommendation adds further investor appeal, though the stock may already reflect some of this optimism given the year-long uptrend.